The skin cancer test developer reported total revenues of $14.8 million compared to $3.7 in Q3 2018, beating the Wall Street expectation of $9.5 million.
The pilot study with the Mayo Clinic is the final step before SkylineDx commences a US trial next year for its molecular test for primary cutaneous melanoma.
The researchers said that they have demonstrated an approach that skirts a bottleneck and enables building pathology support systems from large datasets.
Using genetic information from cancer cells, SkylineDx is developing its test to predict whether a patient is at risk of having metastases in the lymph nodes,
